Global analysis of differentially expressed genes in androgen-independent prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 10, Issue 2, 2007, Pages 167-174

  Wei, Q ^a   Li, M ^b   Fu, X ^a   Tang, R ^a   Na, Y ^b   Jiang, M ^a   Li, Y ^a  

^a FUDAN UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; GENE PRODUCT; JANUS KINASE 2; RIBOSOME PROTEIN; RIBOSOME PROTEIN S19; THIOREDOXIN; THIOREDOXIN DOMAIN CONTAINING 5 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HORMONE DEPENDENCE; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN FAMILY; UPREGULATION;

ANDROGEN ANTAGONISTS; ANDROGENS; GENE EXPRESSION PROFILING; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS;

EID: 34250008248     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500933     Document Type: Article

References (62)

1. Eisenberger MA, Carducci MA. Chemotherapy for hormone-resistant prostate cancer. In:WAlsh PC, Retik AB, Vaughan DE, Wein AJ (eds). Campbells Urology, 8th edn. Elsevier: Philadelphia, 1998, pp 3209-3226.
2. Logothetis CJ, Hoosein NM, Hsieh JT. The clinical and biological study of androgen independent prostate cancer (AI PCa). Semin Oncol 1994; 21: 620-629.
3. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332 1393-1398.
4. Naslund MJ, Coffey DS. The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth. J Urol 1986; 136: 1136-1140.
5. Bektic J, Wrulich OA, Dobler G, Kofler K, Ueberall F, Culig Z et al. Identification of genes involved in estrogenic action in the human prostate using microarray analysis. Genomics 2004; 83: 34-44.
6. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994; 12: 454-466.
7. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997; 157: 2323-2328.
8. Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000; 6: 1882-1890.
9. Holloway AJ, van Laar RK, Tothill RW, Bowtell DD. Options available-from start to finish-for obtaining data from DNA microarrays II. Nat Genet 2002; 32 (Suppl): 481-489.
10. Li Y, Li Y, Tang R, Xu H, Qiu M, Chen Q et al. Discovery and analysis of hepatocellular carcinoma genes using cDNA microarrays. J Cancer Res Clin Oncol 2002; 128: 369-379 [E-pub 20 June 2002].
11. Sambrook J, Russell DW. Using PCR to amplify DNA in vitro. In: Argentine J (ed) Molecular Cloning: A Laboratory Manual, 3rd edn. Cold Spring Harbor Laboratory Press: NY, 2001.
12. Berger JA, Hautaniemi S, Jarvinen AK, Edgren H, Mitra SK, Astola J. Optimized LOWESS normalization parameter selection for DNA microarray data. BMC Bioinformatics; 2004; 5: 194.
13. Gunawardena RW, Siddiqui H, Solomon DA, Mayhew CN, Held J, Angus SP et al. Hierarchical requirement of SWI/SNF in retinoblastoma tumor suppressor-mediated repression of Plk1. J Biol Chem 2004; 279 29278-29285.
14. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94: 148-152.
15. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O. Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1. Oncogene 2003; 22: 8952-8955.
16. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100: 5789-5794.
17. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004; 60: 240-245.
18. Schafer B, Marg B, Gschwind A, Ullrich A. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem 2004; 279: 47929-47938 [E-pub 26 August 2006].
19. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 12003; 22: 1114-1124.
20. Ding X, Yang LY, Huang GW, Wang W, Lu WQ. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastroenterol 2004; 10: 2735-2739.
21. Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin MF et al. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol 2003; 23: 1365-1371.
22. Kudo Y, Kitajima S, Ogawa I, Kitagawa M, Miyauchi M, Takata T. Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol Cancer Ther 2005; 4: 471-476.
23. Jiang F, Caraway NP, Li R, Katz RL. RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells. Oncogene 2005; 24: 3409-3418.
24. Li JQ, Wu F, Masaki T, Kubo A, Fujita J, Dixon DA et al. Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. Int J Oncol 2004; 25: 87-95.
25. Shigemasa K, Gu L, O'Brien TJ, Ohama K. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res 2003; 9: 1756-1763.
26. Lu L, Schulz H, Wolf DA. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol 2002; 3: 22 [E-pub 20 August 2002].
27. Gillette JM, Chan DC, Nielsen-Preiss SM. Annexin 2 expression is reduced in human osteosarcoma metastases. J Cell Biochem 2004; 92: 820-832.
28. Liu JW, Shen JJ, Tanzillo-Swarts A, Bhatia B, Maldonado CM, Person MD et al. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003; 22: 1475-1485.
29. Wang HT, Kong JP, Ding F, Wang XQ, Wang MR, Liu LX et al. Analysis of gene expression profile induced by EMP-1 in esophageal cancer cells using cDNA Microarray. World J Gastroenterol 2003; 9: 392-398.
30. Sullivan DC, Huminiecki L, Moore JW, Boyle JJ, Poulsom R, Creamer D et al. EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem 2003; 278: 47079-47088 [E-pub 8 September 2003].
31. Koyama S, Koike N, Adachi S. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: A possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol 2002; 128: 73-79 [E-pub 12 December 2001].
32. Kim R, Tanabe K, Emi M, Uchida Y, Toge T. Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells. Oncol Rep 2003; 10: 1925-1930.
33. Li B, Sun M, He B, Yu J, Zhang YD, Zhang YL. Identification of differentially expressed genes in human uterine leiomyomas using differential display. Cell Res 2002; 12: 39-45.
34. Zhang X, Grand RJ, McCabe CJ, Franklyn JA, Gallimore PH, Turnell AS. Transcriptional regulation of the human glycoprotein hormone common alpha subunit gene by cAMP-response-element-binding protein (CREB)-binding protein (CBP)/p300 and p53. Biochem J 2002; 368 (Part 1): 191-201.
35. Graichen R, Liu D, Sun Y, Lee KO, Lobie PE. Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells. J Biol Chem 2002; 277: 26662-26672 [E-pub 6 May 2002].
36. Berns EM, Dirkzwager-Kiel MJ, Kuenen-Boumeester V, Timmermans M, Verhoog LC, van den Ouweland AM et al. Androgen pathway dysregulation in BRCA1-mutated breast tumors. Breast Cancer Res Treat 2003; 79 121-127.
37. Hayami R, Sato K, Wu W, Nishikawa T, Hiroi J, Ohtani-Kaneko R et al. Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. Cancer Res 2005; 65: 6-10.
38. Gao B, Shen X, Kunos G, Meng Q, Goldberg ID, Rosen EM et al. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 2001; 488: 179-184.
39. Clark BJ, Li J. Janus kinase 2 signaling in the angiotensin II-dependent activation of StAR expression. Endocr Res 2004; 30: 685-693.
40. Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH et al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA 2003; 100: 1016-1021 [E-pub 27 January 2003].
41. Leav I, Merk FB, Kwan PW, Ho SM. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 1989; 15: 23-40.
42. Aguilar R, Bellido C, Benitez de Lupo EA. Differences in prepuberal neonatally estrogenized or androgenized male rats. Andrologia 1987; 19: 183-187.
43. Tynan S, Pacia E, Haynes-Johnson D, Lawrence D, D'Andrea MR, Guo JZ et al. The putative tumor suppressor deleted in malignant brain tumors 1 is an estrogen-regulated gene in rodent and primate endometrial epithelium. Endocrinology 2005; 146: 1066-1073.
44. Braidotti P, Nuciforo PG, Mollenhauer J, Poustka A, Pellegrini C, Moro A et al. DMBT1 expression is down-regulated in breast cancer. BMC Cancer 2004; 4: 46.
45. Mollenhauer J, Herbertz S, Helmke B, Kollender G, Krebs I, Madsen J et al. Deleted in 1 is a versatile mucin-like molecule likely to play a differential role in digestive tract cancer. Cancer Res 2001; 61: 8880-8886.
46. Ma JF, Takito J, Vijayakumar S, Peehl DM, Olsson CA, Al-Awqati Q. Prostatic expression of hensin, a protein implicated in epithelial terminal differentiation. Prostate 2001; 49: 9-18.
47. Jung DJ, Sung HS, Goo YW, Lee HM, Park OK, Jung SY et al. Novel transcription coactivator complex containing activating signal cointegrator 1. Mol Cell Biol 2002; 22: 5203-5211.
48. Palmer DH, Hussain SA, Ganesan R, Cooke PW, Wallace DM, Young LS et al. CD40 expression in prostate cancer: A potential diagnostic and therapeutic molecule. Oncol Rep 2004; 12: 679-682.
49. Yamaguchi H, Tanaka F, Sadanaga N, Ohta M, Inoue H, Mori M. Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells. Int J Oncol 2003; 23: 1697-1702.
50. Deregibus MC, Buttiglieri S, Russo S, Bussolati B, Camussi G. CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J Biol Chem 2003; 278: 18008-18014.
51. Cao LP, Bolt MJ, Wei M, Sitrin MD, Chun Li Y. Regulation of calbindin-D9k expression by 1,25-dihydroxyvitamin D(3) and parathyroid hormone in mouse primary renal tubular cells. Arch Biochem Biophys 2002; 400: 118-124.
52. Komatsu K, Murata K, Kameyama M, Ayaki M, Mukai M, Ishiguro S et al. Expression of S100A6 and S100A4 in matched samples of human colorectal mucosa, primary colorectal adenocarcinomas and liver metastases. Oncology 2002; 63: 192-200.
53. Srinivasan S, Bunch DO, Feng Y, Rodriguiz RM, Li M, Ravenell RL et al. Deficits in reproduction and pro-gonadotropin-releasing hormone processing in male Cpefat mice. Endocrinology 2004; 145: 2023-2034 [E-pub 8 January 2004].
54. Hougaard DM, Larsson LI. Carboxypeptidase E in rat antropyloric mucosa: distribution in progenitor and mature endocrine cell types. Histochem Cell Biol 2004;121:55-61 [E-pub 6 Decemebr 2003].
55. Slongo ML, Zampieri M, Onisto M. Expression of matrix metalloproteases (MMP-2, MT1-MMP) and their tissue inhibitor (TIMP-2) by rat sertoli cells in culture: Implications for spermatogenesis. Biol Chem 2002; 383: 235-239.
56. Ylitalo K, Nuotio I, Viikari J, Auwerx J, Vidal H, Taskinen MR. C3, hormone-sensitive lipase, and peroxisome proliferator-activated receptor gamma expression in adipose tissue of familial combined hyperlipidemia patients. Metabolism 2002; 51: 664-670.
57. Bednarek MA, Feighner SD, Hreniuk DL, Palyha CC, Morin NR, Sadowski SJ et al. Short segment of human melanin-concentrating hormone that is sufficient for full activation of human melanin-concentrating hormone receptors 1 and 2. Biochemistry 2001; 40: 9379-9386.
58. Fernandez A, Udagawa T, Schwesinger C, Beecken W, Achilles-Gerte E, McDonnell T et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001; 93: 208-213.
59. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): Inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9: 407-415.
60. Cross NA, Chandrasekharan S, Jokonya N, Fowles A, Hamdy FC, Buttle DJ et al. The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: Relevance to the accumulation of versican. Prostate 2005; 63: 269-275.
61. Darnton SJ, Hardie LJ, Muc RS, Wild CP, Casson AG. Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: Loss of expression correlates with poor prognosis. Int J Cancer 2005; 115: 351-358.
62. Miyazaki T, Kato H, Nakajima M, Faried A, Takita J, Sohda M et al. An immunohistochemical study of TIMP-3 expression in oesophageal squamous cell carcinoma. Br J Cancer 2004; 91: 1556-1560.